Genovis AB (publ.) Cash Flow Conversion Efficiency
Genovis AB (publ.) cash flow conversion efficiency. Based on the latest financial reports, Genovis AB (publ.) (GENO) has a cash flow conversion efficiency ratio of 0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr15.90 Million ≈ $1.71 Million USD) by net assets (Skr271.52 Million ≈ $29.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Genovis AB (publ.) (2008–2025)
Cash flow conversion efficiency of Genovis AB (publ.) from 2008 to 2025. This chart illustrates how Genovis AB (publ.)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Genovis AB (publ.) stock quote for real-time trading data and today's change.
Genovis AB (publ.) Cash Flow Conversion Ratio Explained
Genovis AB (publ.) cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Genovis AB (publ.) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genovis AB (publ.) ranked by their cash flow conversion efficiency. Also see GENO stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AIRO Group Holdings, Inc. Common Stock
NASDAQ:AIRO
|
-0.008x |
|
First Capital Inc
NASDAQ:FCAP
|
0.060x |
|
Xiongan Kerong Environment Technology Co Ltd
SHE:300152
|
-0.004x |
|
Bosung Power Technology Co. Ltd
KQ:006910
|
0.080x |
|
Sangoma Technologies Corp
TO:STC
|
0.046x |
|
Norcod As
OL:NCOD
|
-0.333x |
|
Alicon Castalloy Limited
NSE:ALICON
|
0.185x |
|
COPRD
NYSE MKT:COPRD
|
0.022x |
Annual Cash Flow Conversion Efficiency for Genovis AB (publ.) (2008–2025)
The table below shows the annual cash flow conversion efficiency of Genovis AB (publ.) from 2008 to 2025. Review Genovis AB (publ.) (GENO) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr271.52 Million ≈ $29.22 Million |
Skr32.02 Million ≈ $3.45 Million |
0.118x | -27.56% |
| 2024-12-31 | Skr227.97 Million ≈ $24.53 Million |
Skr37.12 Million ≈ $3.99 Million |
0.163x | -54.15% |
| 2023-12-31 | Skr190.81 Million ≈ $20.53 Million |
Skr67.75 Million ≈ $7.29 Million |
0.355x | +4908.05% |
| 2022-12-31 | Skr125.65 Million ≈ $13.52 Million |
Skr-927.95K ≈ $-99.86K |
-0.007x | -101.83% |
| 2021-12-31 | Skr113.99 Million ≈ $12.27 Million |
Skr45.92 Million ≈ $4.94 Million |
0.403x | +835.02% |
| 2020-12-31 | Skr87.17 Million ≈ $9.38 Million |
Skr3.76 Million ≈ $404.12K |
0.043x | -88.31% |
| 2019-12-31 | Skr35.62 Million ≈ $3.83 Million |
Skr13.13 Million ≈ $1.41 Million |
0.368x | +868.80% |
| 2018-12-31 | Skr26.07 Million ≈ $2.81 Million |
Skr-1.25 Million ≈ $-134.48K |
-0.048x | +89.57% |
| 2017-12-31 | Skr18.19 Million ≈ $1.96 Million |
Skr-8.36 Million ≈ $-899.14K |
-0.459x | +55.57% |
| 2016-12-31 | Skr15.55 Million ≈ $1.67 Million |
Skr-16.08 Million ≈ $-1.73 Million |
-1.034x | +43.40% |
| 2015-12-31 | Skr8.82 Million ≈ $949.39K |
Skr-16.12 Million ≈ $-1.73 Million |
-1.827x | -20.06% |
| 2014-12-31 | Skr14.58 Million ≈ $1.57 Million |
Skr-22.19 Million ≈ $-2.39 Million |
-1.522x | -303.82% |
| 2013-12-31 | Skr33.09 Million ≈ $3.56 Million |
Skr-12.47 Million ≈ $-1.34 Million |
-0.377x | +65.40% |
| 2012-12-31 | Skr13.63 Million ≈ $1.47 Million |
Skr-14.85 Million ≈ $-1.60 Million |
-1.089x | -61.46% |
| 2011-12-31 | Skr18.01 Million ≈ $1.94 Million |
Skr-12.15 Million ≈ $-1.31 Million |
-0.675x | +2.00% |
| 2010-12-31 | Skr15.23 Million ≈ $1.64 Million |
Skr-10.48 Million ≈ $-1.13 Million |
-0.688x | +45.43% |
| 2009-12-31 | Skr10.86 Million ≈ $1.17 Million |
Skr-13.70 Million ≈ $-1.47 Million |
-1.261x | +49.75% |
| 2008-12-31 | Skr6.68 Million ≈ $718.56K |
Skr-16.76 Million ≈ $-1.80 Million |
-2.510x | -- |
About Genovis AB (publ.)
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an… Read more